Achaogen (AKAO) Misses Q1 EPS by 17c, Beats on Revenues

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. GILD
9. SBUX
10. SNDK

Go back to Achaogen (AKAO) Misses Q1 EPS by 17c, Beats on Revenues

Guggenheim Downgrades Achaogen (AKAO) to Neutral Citing Valuation

May 7, 2018 7:46 AM EDT

Guggenheim downgraded Achaogen (NASDAQ: AKAO) from Buy to Neutral.

For an analyst ratings summary and ratings history on Achaogen click here. For more ratings news on Achaogen click here.

Shares of Achaogen closed at $11.71 Friday.

... More

Achaogen (AKAO) PT Lowered to $16 at SunTrust Robinson Humphrey

May 3, 2018 8:37 AM EDT

SunTrust Robinson Humphrey lowered its price target on Achaogen (NASDAQ: AKAO) to $16.00 (from $27.00) while maintaining a Buy rating.

... More

Achaogen (AKAO) PT Lowered to $19 at H.C. Wainwright

May 3, 2018 7:45 AM EDT

H.C. Wainwright lowered its price target on Achaogen (NASDAQ: AKAO) to $19.00 (from $29.00) while maintaining a Buy rating.

... More

Achaogen (AKAO) PT Lowered to $20 at Mizuho Securities

May 3, 2018 4:03 AM EDT

Mizuho Securities lowered its price target on Achaogen (NASDAQ: AKAO) to $20.00 (from $28.00) while maintaining a Buy rating.

... More

Achaogen (AKAO) to Resume Trading at 5:40 pm ET

May 2, 2018 5:20 PM EDT

Achaogen (NASDAQ: AKAO) to Resume Trading at 5:40 pm ET

... More

Achaogen (AKAO) Provides Summary of FDA Advisory Committee Votes on Plazomicin

May 2, 2018 5:13 PM EDT

Achaogen, Inc. (NASDAQ: AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that the U.S. Food and Drug Administration's (FDA) Antimicrobial Drugs Advisory Committee voted on the two points for Advisory Committee consideration as follows:

1. Has the applicant provided substantial evidence of the safety and effectiveness of plazomicin for the treatment of complicated urinary tract... More

Achaogen (AKAO) Confirms Stock Halted Ahead of FDA Panel to Review Plazomicin

May 2, 2018 7:24 AM EDT

Achaogen, Inc. (NASDAQ: AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that NASDAQ has halted trading of the Companys common stock.

The U.S. Food and Drug Administrations (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) is meeting today to review plazomicin, which was developed for the treatment of adults with complicated urinary tract infections and... More

Achaogen (AKAO) Halted, News Pending

May 2, 2018 6:59 AM EDT

Achaogen (NASDAQ: AKAO) Halted, News Pending

... More